Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Degludec effectively lowers blood glucose with lower risk for hypoglycemia

An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Diabetes is the number 1 cause of neuropathy, which is a very common condition in itself. In fact, up to half of all neuropathy is caused by diabetes, although other people can get the condition as well.

25 Jun 2012

Major advance in development of night-time automatic control device for blood glucose levels at home

Yet another exciting breakthrough took place yesterday in the advancement and development of the ARTIFICIAL PANCREAS by specialists at Schneider Children's Medical Center of Israel.

18 Jun 2012

Insulin more effective add-on than sitagliptin in glucose control

Insulin seems to be a more effective add-on regimen than sitagliptin in patients with diabetes inadequately controlled by metformin monotherapy, show study findings.

15 Jun 2012

Controlled blood sugar in diabetes can prevent painful nerves: but at what cost?

Aggressive control of blood sugar levels in diabetes can help to prevent a painful condition affecting patients’ nerves, according to a new systematic review in The Cochrane Library. However, the review suggests that optimal target levels need to be established to prevent serious complications.

13 Jun 2012

Liquid glucagon formulation may be useable in standard diabetes pumps

JDRF-funded researchers at Oregon Health & Science University (OHSU) and Legacy Health have discovered a liquid glucagon formulation that may be useable in standard diabetes pumps.

13 Jun 2012

Long-term insulin use does not increase risk of heart disease in people with diabetes

Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.

13 Jun 2012

Data from first feasibility study of artificial pancreas system

Results from the first feasibility study of an advanced first-generation artificial pancreas system were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely.

11 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes

Amylin Pharmaceuticals, Inc. today announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate) injection treatment was used along with insulin.

11 Jun 2012

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.

11 Jun 2012

Intensive glucose control associated with reduced risk of albuminuria

A review of data from seven clinical trials suggests that intensive glucose control is associated with reduced risk of microalbuminuria and macroalbuminuria (conditions characterized by excessive levels of protein in the urine usually resulting from damage to the filtering units of the kidneys), according to a report published in the May 28 issue of Archives of Internal Medicine, a JAMA Network publication.

29 May 2012

Linagliptin safe and effective for African American patients with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African American adult patients with type 2 diabetes whose blood sugar was not adequately controlled.

25 May 2012

Glytec receives FDA clearance for Glucommander 2.0 Enterprise software

Glytec, LLC, headquartered in Greenville, SC, announced today that its Glucommander 2.0 Enterprise software has been cleared by the FDA for pediatric use, ages 2 - 17.

22 May 2012

Hygieia’s DIGS automatically adjusts insulin dosage in patients with diabetes

Newly published results from a clinical study of the Diabetes Insulin Guidance System (DIGS-), under development by Hygieia, Inc., demonstrate DIGS' potential to improve blood glucose control for insulin-using patients with type 2 or type 1 diabetes. DIGS automatically adjusted insulin dosage based on each individual's reported blood glucose results.

10 May 2012

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes.

4 May 2012

Beta cells from genetically modified pigs can effectively restore pancreas function

Transplantation of a whole pancreas or isolated insulin-producing beta cells are the only therapy to cure type 1 diabetes. However, the shortage of organ donors limits this approach to only few patients. LMU researchers have now shown that beta cells from genetically modified pigs can effectively restore pancreas function and can protect porcine beta cells from immune rejection in animal models.

23 Apr 2012

Positive top-line results from Biodel’s Phase 1 trial of two RHI-based formulations

Biodel Inc. today announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting formulations of recombinant human insulin.

16 Apr 2012

European Commission grants marketing authorization for use of BYETTA with basal insulin

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced today that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

23 Mar 2012

Hypoglycemia News and Research

Further Reading

Degludec effectively lowers blood glucose with lower risk for hypoglycemia

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Major advance in development of night-time automatic control device for blood glucose levels at home

Insulin more effective add-on than sitagliptin in glucose control

Controlled blood sugar in diabetes can prevent painful nerves: but at what cost?

Liquid glucagon formulation may be useable in standard diabetes pumps

Long-term insulin use does not increase risk of heart disease in people with diabetes

Data from first feasibility study of artificial pancreas system

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Intensive glucose control associated with reduced risk of albuminuria

Linagliptin safe and effective for African American patients with type 2 diabetes

Glytec receives FDA clearance for Glucommander 2.0 Enterprise software

Hygieia’s DIGS automatically adjusts insulin dosage in patients with diabetes

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Beta cells from genetically modified pigs can effectively restore pancreas function

Positive top-line results from Biodel’s Phase 1 trial of two RHI-based formulations

European Commission grants marketing authorization for use of BYETTA with basal insulin

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News